{"entity":{"id":"richard-baum","kind":"person","name":"Richard P. Baum","aka":[],"tldr":"One of the pioneers of peptide receptor radionuclide therapy for neuroendocrine tumours, now practising at the Curanosticum theranostics centre in Wiesbaden.","summary":"Richard Baum is a specialist in nuclear medicine whom Curanosticum describes as one of the leading experts in therapeutic nuclear medicine and part of its medical team since 2020. The centre offers PET-CT, radioiodine therapy, PSMA radioligand therapy and DOTATOC receptor radionuclide therapy. Before Wiesbaden he built the theranostics programme at the Zentralklinik Bad Berka, where lutetium-177 and yttrium-90 labelled somatostatin analogues were used to treat thousands of patients with neuroendocrine tumours, work that preceded the approvals of lutetium-177 dotatate and lutetium-177 PSMA-617. His publications are listed on PubMed.","asOf":"2026-09-17","links":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"tags":["leadership"],"related":[],"cancers":["neuroendocrine","prostate"],"sections":[],"technologies":["radioligand-therapy","lu177-radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["curanosticum"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Nuclear medicine specialist, Curanosticum Wiesbaden-Frankfurt","institutionId":"curanosticum","specialisms":["Nuclear medicine","Peptide receptor radionuclide therapy","PSMA radioligand therapy","Theranostics"],"profiles":[{"label":"Curanosticum","url":"https://www.curanosticum.de/en/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide"}],"papers":[{"title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","journal":"New England Journal of Medicine","year":2017,"url":"https://doi.org/10.1056/NEJMoa1607427","doi":"10.1056/NEJMoa1607427","note":"Europe PMC author record matched by affiliation"},{"title":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0","journal":"European Journal of Nuclear Medicine and Molecular Imaging","year":2010,"url":"https://doi.org/10.1007/s00259-009-1297-4","doi":"10.1007/s00259-009-1297-4","note":"Europe PMC author record matched by affiliation"},{"title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","journal":"Journal of Nuclear Medicine","year":2017,"url":"https://doi.org/10.2967/jnumed.116.183194","doi":"10.2967/jnumed.116.183194","note":"Europe PMC author record matched by affiliation"}]},"route":"/people/richard-baum/","neighbours":{"cancer":[{"id":"neuroendocrine","kind":"cancer","name":"Neuroendocrine tumours","route":"/cancers/neuroendocrine/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"technology":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/"},{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/"}],"institution":[{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/"}]}}